Previous 10 | Next 10 |
Abiomed ( ABMD ) Q4 results : More news on: Abiomed, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
FY 2020 Annual Revenue of $841 Million, Up 9%, and 29.6% Operating Margin Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported fourth quarter fiscal 2020 revenue of $206.7 million compared to revenue of $207.1 million for the...
Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no l...
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, April 30, 2020, the Company will release financial results for the fourth quarter of fiscal 2020. The Company will host a conference call to discuss the results on Thursday, April 30, 2020, at 8:00 a.m. ET. Michael R. Minogue, Chairma...
Abiomed (NASDAQ: ABMD ) takes following steps during the COVID-19 outbreak. More news on: Abiomed, Inc., Healthcare stocks news, Read more ...
Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, is taking a number of steps to aid the global medical community and contribute to improved patient care during the COVID-19 outbreak. Impella heart pumps are FDA approved to provide circulatory support to allow the heart to rest and...
Abiomed ( ABMD ) develops, manufactures and markets products heart devices including pumps. The company's product portfolio includes the Impella heart pumps and SmartAssist technology. The company has been on my watch-list as an investment opportunity since Oct 12 2019 after it reported issue...
The artificial heart is very effective as a bridge to transplant, but the number of people that can be saved with human hearts is limited. A perfect artificial heart could save many more patients. - Robert Jarvik Impella, Abiomed’s ( ABMD ) artificial heart, has been in the market s...
Ardelyx (NASDAQ: ARDX ) initiated with Buy rating and $13 (75% upside) price target at Citigroup. Shares up 5% premarket. More news on: Ardelyx, Inc., I-Mab, Palatin Technologies, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Image source: The Motley Fool. Abiomed Inc (NASDAQ: ABMD) Q3 2020 Earnings Call Feb 6, 2020 , 8:00 a.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...